Basic information
Biomarker: MMR protein
Histology type: endometrial carcinoma
Cohort characteristics
Country: Finland
Region: Helsinki
Study type: single institution retrospective study
Followed up time :
Subgroup 1 name : MMR-D
Subgroup 1 number: 287
Subgroup 2 name: NSMP
Subgroup 2 number: 218
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 505 | MMR-D cohort | 287 | NSMP subgroup | 218 |
Sample information
Conclusion: MMR protein and MLH1 methylation status predict the response to adjuvant therapy in endometrial cancer.
Sample type : tissue
Sample method: immunohistochemistry,Methylation‐specific multiplex ligation‐dependent probe amplification,
Expression pattern : methylation status
Expression elevation: MMR deficient (MMR‐D) tumors were identified as MLH1 methylated or nonmethylated by methylation‐specific multiplex ligation‐dependent probe amplification. .Tumors with a methylation ratio >0.15 (corresponding to 15% of methylated DNA) in region C and/or region D were considered hypermethylated.
Disease information
Statictics: Mean (SD);Range
Subgroup 1 age: 70;61–77
Subgroup 2 age: 66;60–73
Related information
UniProt Link:
Molecular function from UniProt:
Survival figure legend: Cox regression disease‐specific survival plots for (A) mismatch repair deficient (MMR‐D) and (B) “no specific molecular profile” (NSMP) subgroups. VBT, vaginal brachytherapy; WPRT, whole pelvic radiotherapy
Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897956/figure/cam43691-fig-0002/
